Compare NOG & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOG | TVTX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | 2000 | 2013 |
| Metric | NOG | TVTX |
|---|---|---|
| Price | $28.46 | $27.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $31.00 | ★ $36.25 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.50% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $2,475,723,000.00 | N/A |
| Revenue This Year | $8.21 | $44.62 |
| Revenue Next Year | $4.24 | $32.09 |
| P/E Ratio | $71.12 | ★ N/A |
| Revenue Growth | ★ 11.23 | N/A |
| 52 Week Low | $19.88 | $12.91 |
| 52 Week High | $32.62 | $42.13 |
| Indicator | NOG | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.90 | 43.03 |
| Support Level | $26.58 | $26.72 |
| Resistance Level | $28.59 | $31.47 |
| Average True Range (ATR) | 1.19 | 1.03 |
| MACD | -0.14 | -0.01 |
| Stochastic Oscillator | 67.79 | 33.52 |
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.